Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24508251 | 1.00 | EPHX2 (0.43) | EPHX2MEN1KMT2AFAAHGLP1R | |
| SCHEMBL24029656 | 0.92 | FAAH (0.44) | MEN1KMT2AFAAHLMNATSHR | |
| SCHEMBL25654169 | 0.91 | EPHX2 (0.39) | EPHX2MEN1KMT2AFAAHGLP1R | |
| SCHEMBL23695885 | 0.89 | KMT2A (0.50) | MEN1KMT2AGLP1RLMNATSHR | |
| SCHEMBL22856479 | 0.89 | KMT2A (0.50) | MEN1KMT2AGLP1RLMNATSHR | |
| SCHEMBL23696368 | 0.88 | EPHX2 (0.41) | EPHX2MEN1KMT2AFAAHGLP1R | |
| SCHEMBL22837679 | 0.88 | EPHX2 (0.45) | EPHX2MEN1KMT2AFAAHGLP1R | |
| SCHEMBL21105769 | 0.88 | EPHX2 (0.45) | EPHX2MEN1KMT2AFAAHGLP1R | |
| SCHEMBL25884894 | 0.88 | EPHX2 (0.45) | EPHX2MEN1KMT2AFAAHGLP1R | |
| SCHEMBL25921938 | 0.88 | EPHX2 (0.37) | EPHX2KMT2AFAAHGLP1RLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885MEN1 4055/4885KMT2A 445/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885MEN1 4055/4885KMT2A 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.